Abstract

Objectives: Non-dystrophic myotonias (NDM) are rare diseases due to mutations in the voltage-gated sodium (Nav1.4) and chloride (ClC-1) channels expressed in skeletal muscle fibers. We provide an up-to-date review of pharmacological treatments available for NDM patients and experimental studies aimed at identifying alternative treatments and at better understanding the mechanisms of actions.

Methods: Literature research was performed using PubMed and ClinicalTrial.gov.

Results: Today, the sodium channel blocker mexiletine is the drug of choice for treatment of NDM. Alternative drugs include other sodium channel blockers and the carbonic anhydrase inhibitor acetazolamide. Preclinical studies suggest that activators of ClC-1 channels or voltage-gated potassium channels may have antimyotonic potential. 

Conclusions: An increasing number of antimyotonic drugs would help to design a precision therapy to address personalized treatment of myotonic individuals.

Downloads

PDF
Authors

Jean-François Desaphy - Section of Pharmacology, Department of Precision and Regenerative Medicine and Ionian Area, School of Medicine, University of Bari Aldo Moro, Bari, Italy

Ilaria Saltarella - Section of Pharmacology, Department of Precision and Regenerative Medicine and Ionian Area, School of Medicine, University of Bari Aldo Moro, Bari, Italy

Paola Laghetti - Section of Pharmacology, Department of Precision and Regenerative Medicine and Ionian Area, School of Medicine, University of Bari Aldo Moro, Bari, Italy

Simone Dell'Atti - Section of Pharmacology, Department of Precision and Regenerative Medicine and Ionian Area, School of Medicine, University of Bari Aldo Moro, Bari, Italy

Concetta Altamura - Section of Pharmacology, Department of Precision and Regenerative Medicine and Ionian Area, School of Medicine, University of Bari Aldo Moro, Bari, Italy

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright

Copyright (c) 2025 Acta Myologica

How to Cite
Desaphy, J.-F., Saltarella, I., Laghetti, P., Dell’Atti, S., & Altamura, C. (2025). Pharmacological therapy of non-dystrophic myotonias. Acta Myologica, 44(1). https://doi.org/10.36185/2532-1900-1026
  • Abstract viewed - 540 times
  • PDF downloaded - 180 times